🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,041 results for “Advanced” Clear

  1. EIK1005

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  2. EIK1005 10mg Tablets, EIK1005 50mg Tablets, PEMBROLIZUMAB , EIK1005 200mg Tablets

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  3. ENMD-2076

    CASI Pharmaceuticals

    Advanced Adult Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  4. Early recognition of progressive lung fibrosis in systemic rheumatic diseases: a characterization of the pulmonary environment through extracellular vesicles, advanced and functional imaging

    Fondazione Telethon ETS

    Patients with connective tissue diseases at high risk of interstial lung disease

    phase 2 other active

    1 trial

  5. Entinostat

    KYOWA KIRIN AUSTRALIA PTY LTD

    Advanced or Recurrent Breast Cancer

    phase 2 small molecule completed

    1 trial

  6. Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum)

    CERO THERAPEUTICS HOLDINGS, INC.

    Rectal adenocarcinoma

    phase 2 other active

    1 trial

  7. Experimental

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer (LARC)

    phase 2 small molecule active

    1 trial

  8. FULVESTRANT, LETROZOLE

    Pfizer Australia Pty Ltd

    HR-positive HER2-negative metastatic/advanced BC

    phase 2 small molecule active

    1 trial

  9. FULVESTRANT, M1774 50mg, M1774 30mg

    The George Institute

    advanced breast cancer

    phase 2 small molecule active

    1 trial

  10. FULVESTRANT, camizestrant, camizestrant

    AstraZeneca AB

    Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  11. Fentanyl Buccal Tablet

    Teva Pharma GmbH

    Advanced Cancers

    phase 2 small molecule completed

    1 trial

  12. Fianlimab

    Regeneron UK Limited

    Advanced Renal Cell Carcinoma (aRCC)

    phase 2 small molecule active

    1 trial

  13. Fianlimab

    Regeneron UK Limited

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  14. Fibromun, Darleukin

    Philogen S.p.A.

    Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.

    phase 2 small molecule active

    1 trial

  15. Fulvestrant

    United Therapeutics Europe Ltd

    Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  16. Futibatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  17. Futibatinib, Tecentriq 1 200 mg concentrate for solution for infusion, JNJ-61186372

    The George Institute

    Subjects with advanced solid tumour

    phase 2 small molecule active

    1 trial

  18. GEMCITABINE ARROW 40 mg/ml, solution à diluer pour perfusion, Berzosertib (M6620)

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas.

    phase 2 small molecule active

    1 trial

  19. GIOTRIF 40 mg film-coated tablets, GIOTRIF 30 mg film-coated tablets, GIOTRIF 20 mg film-coated tablets

    The George Institute

    Patients diagnosed with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx secondary to Fanconi anemia.

    phase 2 small molecule active

    1 trial

  20. Gamma-retroviral vector MP71 MC2 TCR16-3D9

    Disc Medicine

    advanced melanoma or HNSCC

    phase 2 small molecule active

    1 trial

  21. Gemcitabine

    LEXICON PHARMACEUTICALS, INC.

    Locally Advanced Unresectable Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  22. Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  23. Gentuximab

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  24. Gentuximab

    Changchun GeneScience Pharmaceutical Co.,

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources